Back To Search Instructions
Protocols
13 protocols meet the specified criteria
Disease Site: Lung
Protocol No.TitleStatus
1403269898Clinical study of the effect of combined treatment of aspirin and zileuton on biomarkers of tobacco-related carcinogenesis in current smokers Open
1408439554A Phase II Randomized Study of Short-Term Dexamethasone Versus Placebo in Patients Receiving Radiation Alone or Radiation and Chemotherapy for the Treatment of Head and Neck and Non-Small Cell Lung CancersOpen
1412588451RANDOMIZED PHASE II TRIAL OF CONCURRENT CHEMORADIOTHERAPY +/- METFORMIN HCL IN LOCALLY ADVANCED NSCLC (NRG-LU001)Open
1504822040S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung CancerOpen
1508022109A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (less than or equal 2 CM) Peripheral Non-Small Cell Lung CancerOpen
1508065953Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (A151216) (A Screening Trial for A081105 and E4512)Open
1509119432A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (ALCHEMIST) (E4512)Open
1509137444Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR)Mutant Non-Small Cell Lung Cancer (NSCLC) (ALCHEMIST) (A081105)Open
1510187282Phase III Comparison Of Thoracic Radiotherapy Regimens In Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin Or Carboplatin And Etoposide (CALGB 30610)Open
1601314096A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer (NRG-CC003) Open
1602381312A PHASE 1A/B STUDY OF THE FOLIC ACID-TUBULYSIN CONJUGATE EC1456 IN PATIENTS WITH ADVANCED SOLID TUMORSOpen
1604536433A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose- Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersOpen
22129Assessment of functional brain changes by FOG-PET Brain Evaluation (FPBE) in cancer patients treated with systemic anticancer therapy.Open